BG-12 for moderate to severe psoriasis - horizon scanning review
NHSC
Record ID 32005000243
English
Authors' objectives:
This study aims to assess the effectiveness of BG-12 for moderate to severe psoriasis.
Authors' recommendations:
BG-12 (dimethyl fumarate) is an orally administered immunomodulator, from a class of products known as fumeric acid esters (FAEs). BG-12 is a second generation FAE product based on Fumaderm (containing mixed dimethyl fumarate and monoethylfumarate salts, and associated with adverse effects) which was licensed in 1994 in Germany for the treatment of psoriasis. There are currently no published trials of clinical effectiveness at this time.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Psoriasis
- Dimethyl Fumarate
- Dermatologic Agents
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.